Halozyme Therapeutics Inc logo

Halozyme Therapeutics Inc(HALO)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
3-STAR RATING
SELL
SELL for 3 days
PROFIT SINCE LAST BUY
+48.11% ▲
LAST CLOSE
$100.27
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for HALO

11/13/2026: HALO (3-star) is a SELL. SELL for 3 days. Simulated Profits (48.11%). Updated daily EoD!

Halozyme Therapeutics is a specialized biotechnology company known for its proprietary ENHANZE drug delivery platform, which converts intravenous treatments into convenient subcutaneous injections. The company's main business strength lies in its asset-light, high-margin royalty model, fueled by stellar sales uptake from blockbuster partner products like DARZALEX SC and VYVGART Hytrulo. Its primary growth story centers on expanding partner pipelines and integrating next-generation device technologies like Hypercon. However, key risks include customer concentration on a few partner drugs and ongoing intellectual property litigation. The stock suits growth-oriented investors willing to monitor partner execution, regulatory milestones, and patent defense developments.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitHalozyme offers robust double-digit revenue and earnings expansion driven by expanding global royalty streams from partner blockbusters.
Momentum investorStrong fit while signal remains positiveThe stock frequently exhibits strong upward price momentum supported by raised financial guidance and strong quarterly outperformance.
Value investorMixed fitWhile trading at attractive price-to-earnings metrics relative to its growth rate, it operates in biotech where sentiment can shift quickly.
Dividend investorWeak fitThe company does not pay a dividend, favoring capital reinvestment and share buybacks instead.
Low-risk investorMediumAlthough it benefits from high profit margins and cash flows, it remains subject to biotechnology sector volatility and partner concentration risks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMedium / highBiotechnology stocks experience periodic price swings based on macro sector sentiment, clinical updates, and litigation outcomes.
Valuation riskMediumMarket expectations are high given strong growth guidance, leaving little room for operational missteps.
Competition risk (partner platform and alternative delivery competition)MediumAlternative formulation technologies or rival delivery systems could threaten long-term partner retention.
Business qualityStrongHalozyme's high-margin royalty model and asset-light structure reflect exceptional underlying franchise quality.
Dividend incomeLow / noneIncome-focused investors will find no dividend support as capital is allocated to growth and buybacks.
Execution riskMediumSuccessful integration of recent acquisitions like Elektrofi and execution on device programs are vital to maintaining growth.

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 11.43B USD
Price to earnings Ratio 25.07
1Y Target Price 119.89
Price to earnings Ratio 25.07
1Y Target Price 119.89
Volume (30-day avg) 2.3M shares
Beta 0.9
52 Weeks Range 61.23 - 134.00
Updated Date 11/15/2026
52 Weeks Range 61.23 - 134.00
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) 4

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit -7.03%
Avg. Invested days 42
Today’s Advisory SELL
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
HALO receives a 4-star rating, supported by strong unit economics, and solid company fundamentals. The rating is constrained by weak price momentum.

Company Fundamentals

★★★★★
HALO has solid overall fundamentals (4 stars), with solid financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, strong cash generation (FCF margin 46.2%) and strong revenue growth (+37.6%) are partially offset by negative earnings growth (-28.6%), modest insider ownership of 2.45%.

Financial Health Rating

★★★★★
HALO's financial health is supported by solid profitability, including gross margin of 83.6% and operating margin of 57.5%. Overall financial-health metrics support a 4-star score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is HALO's strongest growth driver at +37.6% FY2025 versus FY2024 (strong, 5 stars). By comparison, revenue growth (+37.6%, strong) is also strong, while earnings growth (-28.6%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 113.2% and approximately 98.9% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 2.45% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 11.64%
Vanguard Capital Management, LLC 4.69%
Vanguard Portfolio Management, LLC 4.65%
State Street Corp 4.54%
Amvescap Plc. 2.79%

Unit Economics (Per $1K Revenue)

★★★★★
HALO generates approximately $836 of gross profit, $575 of operating income, and $462 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Strong margins, cash conversion, and capital efficiency support the rating.

Economic Dimensions

★★★★★
Effective Tax Rate: 32.13%

Quantitative Style Profile

★★★★★
HALO has a high-quality, large-cap, liquid profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Quality TiltLarge / Mega Cap StabilityShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Royalty RevenuesRoyalty payments collected from commercialized partner products utilizing the ENHANZE technology platform (e.g., DARZALEX SC, Phesgo, VYVGART Hytrulo).This is the core profit engine, acting like a tollbooth on major global biologic blockbusters.
Product Sales & APISales of bulk rHuPH20 enzyme to collaboration partners, specialized proprietary products, and legacy device offerings.Provides reliable recurring manufacturing and material sales tied directly to partner commercial supply chains.
Milestone and Upfront RevenuesContractual milestone payments and licensing fees received upon achieving development, regulatory, or commercial hurdles with partners.Lumpy cash inflows that boost earnings when partner drugs advance successfully through clinical pipelines.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-11-05
When After Market
Estimate 2.17
Actual 2.27

Profitability

Profit Margin 26.93%
Operating Margin (TTM) 56.68%

Management Effectiveness

Return on Assets (TTM) 22.42%
Return on Equity (TTM) 216.38%

Valuation

Trailing PE 25.07
Forward PE 10.56
Enterprise Value 13.61B
Price to Sales(TTM) 6.34
Enterprise Value 13.61B
Price to Sales(TTM) 6.34
Enterprise Value to Revenue 7.55
Enterprise Value to EBITDA 16.89
Shares Outstanding 114.01M
Shares Floating 112.70M
Shares Outstanding 114.01M
Shares Floating 112.70M
Percent Insiders 2.45
Percent Institutions 113.19

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.